ePrints

Advancing the treatment of juvenile idiopathic arthritis

Lookup NU author(s): Dr Ethan SenORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2021 Elsevier Ltd. Treatment for juvenile idiopathic arthritis has undergone substantial changes in recent decades. These changes are partly due to the availability of new treatments, mainly biological agents, as well as developments in treatment strategies, including a focus on concepts such as treat-to-target. In addition, the creation of large paediatric research networks has improved patient access to, and design of, clinical trials for rare paediatric diseases. Although these advances have resulted in improvements in care for most patients with juvenile idiopathic arthritis, certain subgroups of patients continue to have a poor prognosis. Further research aims to identify patients in these subgroups early, to personalise their care, improve functional outcomes, and minimise long-term damage and harm. Optimising the duration of therapy for those individuals who require systemic immunosuppression is also of importance. Incorporation of novel biomarkers in combination with validated clinical measures in an effort to predict outcomes and target therapy accordingly is an exciting development.

Publication metadata

Author(s): Murray GM, Sen ES, Ramanan AV

Publication type: Review

Publication status: Published

Journal: The Lancet Rheumatology

Year: 2021

Volume: 3

Issue: 4

Pages: e294-e305

Print publication date: 01/04/2021

Online publication date: 24/03/2021

Acceptance date: 02/04/2018

ISSN (electronic): 2665-9913

Publisher: Lancet Publishing Group

URL: https://doi.org/10.1016/S2665-9913(20)30426-4

DOI: 10.1016/S2665-9913(20)30426-4

Share